Childhood Adenotonsillectomy Trial

Name

tst1

Label

Date the participant's treatment stopped

Units
seconds from date of randomization
Type
integer

Visit Number vs Date the participant's treatment stopped

N Mean StdDev Median Min Max Unknown Total
Baseline 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 437 464
Follow-up 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453

Treatment Arm vs Date the participant's treatment stopped

Baseline
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
Early adenotonsillectomy (EAT) 10 7,810,560.0 ± 15,472,608.0 2,592,000.0 864,000.0 51,667,200.0 216 226
Watchful waiting with supportive care (WWSC) 17 5,834,541.2 ± 4,533,131.2 5,529,600.0 432,000.0 14,428,800.0 210 227

Treatment Arm vs Date the participant's treatment stopped

Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
Early adenotonsillectomy (EAT) 10 7,810,560.0 ± 15,472,608.0 2,592,000.0 864,000.0 51,667,200.0 216 226
Watchful waiting with supportive care (WWSC) 17 5,834,541.2 ± 4,533,131.2 5,529,600.0 432,000.0 14,428,800.0 210 227

Age vs Date the participant's treatment stopped

Baseline
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
5 - 7 years old 18 6,931,200.0 ± 11,824,962.0 2,376,000.0 432,000.0 51,667,200.0 311 329
8 - 10 years old 9 5,836,800.0 ± 3,932,175.7 5,529,600.0 604,800.0 14,428,800.0 115 124

Age vs Date the participant's treatment stopped

Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 22 6,409,309.1 ± 10,780,105.9 2,592,000.0 432,000.0 51,667,200.0 377 399
5 - 7 years old 15 3,813,120.0 ± 3,389,773.5 2,332,800.0 432,000.0 10,108,800.0 247 262
8 - 10 years old 7 11,972,571.4 ± 18,082,239.4 5,529,600.0 604,800.0 51,667,200.0 130 137

Gender vs Date the participant's treatment stopped

Baseline
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
Female 15 8,046,720.0 ± 12,845,274.1 3,196,800.0 864,000.0 51,667,200.0 219 234
Male 12 4,716,000.0 ± 3,357,688.0 5,529,600.0 432,000.0 10,108,800.0 207 219

Gender vs Date the participant's treatment stopped

Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
Female 15 8,046,720.0 ± 12,845,274.1 3,196,800.0 864,000.0 51,667,200.0 219 234
Male 12 4,716,000.0 ± 3,357,688.0 5,529,600.0 432,000.0 10,108,800.0 207 219

Race vs Date the participant's treatment stopped

Baseline
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
White 9 4,924,800.0 ± 4,904,103.9 3,196,800.0 518,400.0 14,428,800.0 147 156
Black 16 7,279,200.0 ± 12,158,192.1 5,184,000.0 432,000.0 51,667,200.0 233 249
Other 2 8,251,200.0 ± 7,758,941.3 8,251,200.0 2,764,800.0 13,737,600.0 46 48

Race vs Date the participant's treatment stopped

Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 27 6,566,400.0 ± 9,821,459.4 4,233,600.0 432,000.0 51,667,200.0 426 453
White 9 4,924,800.0 ± 4,904,103.9 3,196,800.0 518,400.0 14,428,800.0 147 156
Black 16 7,279,200.0 ± 12,158,192.1 5,184,000.0 432,000.0 51,667,200.0 233 249
Other 2 8,251,200.0 ± 7,758,941.3 8,251,200.0 2,764,800.0 13,737,600.0 46 48